{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T05:37:05Z","timestamp":1762321025820,"version":"build-2065373602"},"reference-count":44,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T00:00:00Z","timestamp":1762300800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Sintilimab plus a Bevacizumab biosimilar (IBI305) is an approved first-line regimen for unresectable hepatocellular carcinoma (uHCC) in China. However, data on its safety and efficacy in patients with impaired liver function remain limited. We assessed the clinical outcomes of this combination therapy in HCC patients with Child-Pugh class A (CP-A) and class B (CP-B) liver function.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In this multicenter retrospective cohort study, 99 patients with advanced uHCC (73 CP-A; 26 CP-B) who received first-line Sin\/Bev were included. Tumor response was assessed using modified RECIST criteria, and adverse events (AEs) were graded per CTCAE v5.0. Survival outcomes, including overall survival (OS), progression-free survival (PFS), and time to hepatic decompensation (TTD), were analyzed via Kaplan-Meier estimates and Cox proportional hazards models.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The objective response rates (ORR) of patients with CP-A and CP-B treated with Sin\/Bev were 50.7% and 57.7%, respectively, and both could achieve good anti-tumor efficacy. CP-B had inferior survival: median OS (15 vs 22 months, p=0.044), PFS (8 vs 14 months, p=0.014), and TTD (7 vs 15 months, p&amp;lt;0.001). The CP-B cohort demonstrated comparable incidence rates of grade 3\u20134 AEs to the CP-A group (34.6% vs 34.2%). Hemorrhagic events and thrombocytopenia emerged as predominant grade 3\u20134 AEs in CP-B patients (15.4% for both).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Sin\/Bev demonstrated encouraging short-term anti-tumor activity in HCC of CP-A and CP-B, while survival outcomes were affected by differences in hepatic function. Although the regimen was generally well tolerated, patients with impaired liver reserve require vigilant monitoring and comprehensive supportive strategies to maximize therapeutic outcomes.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2025.1681663","type":"journal-article","created":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T05:21:52Z","timestamp":1762320112000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Sintilimab plus a bevacizumab biosimilar (IBI305) in advanced HCC with Child-Pugh A\/B liver function: a real-world multicenter retrospective study"],"prefix":"10.3389","volume":"15","author":[{"given":"Yuanxu","family":"Zhang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Youhan","family":"Miao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yixing","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jinjing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuang","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shengwei","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xia","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yang","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiucheng","family":"Pan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weifeng","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,11,5]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21834","article-title":"Global cancer statistics 2022: globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/s2214-109x(19)30488-7","article-title":"Global burden of cancer attributable to infections in 2018: A worldwide incidence analysis","volume":"8","author":"de Martel","year":"2020","journal-title":"Lancet Glob Health"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2021.11.023","article-title":"Global, regional and national burden of primary liver cancer by subtype","volume":"161","author":"Rumgay","year":"2022","journal-title":"Eur J Cancer"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1023\/a:1013747228572","article-title":"Intrahepatic cholangiocarcinoma and hepatitis C and B virus infection, alcohol intake, and hepatolithiasis: A case-control study in Italy","volume":"12","author":"Donato","year":"2001","journal-title":"Cancer Causes Control"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a021535","article-title":"Treatment of liver cancer","volume":"5","author":"Liu","year":"2015","journal-title":"Cold Spring Harb Perspect Med"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2017.03.007","article-title":"The treatment of intermediate stage tumours beyond tace: from surgery to systemic therapy","volume":"67","author":"Galle","year":"2017","journal-title":"J Hepatol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2021.11.018","article-title":"BCLC strategy for prognosis prediction and treatment recommendation: the 2022 update","volume":"76","author":"Reig","year":"2022","journal-title":"J Hepatol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(18)30207-1","article-title":"Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: A randomised phase 3 non-inferiority trial","volume":"391","author":"Kudo","year":"2018","journal-title":"Lancet"},{"key":"B9","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1016\/s1470-2045(21)00151-0","article-title":"Patient-reported outcomes with atezolizumab plus bevacizumab versus sorafenib in patients with unresectable hepatocellular carcinoma (Imbrave150): an open-label, randomised, phase 3 trial","volume":"22","author":"Galle","year":"2021","journal-title":"Lancet Oncol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2024.02.005","article-title":"Four-year overall survival update from the phase iii himalaya study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma","volume":"35","author":"Sangro","year":"2024","journal-title":"Ann Oncol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(25)00403-9","article-title":"Nivolumab plus ipilimumab versus lenvatinib or sorafenib as first-line treatment for unresectable hepatocellular carcinoma (Checkmate 9dw): an open-label, randomised, phase 3 trial","volume":"405","author":"Yau","year":"2025","journal-title":"Lancet"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(23)00961-3","article-title":"Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): A randomised, open-label, international phase 3 study","volume":"402","author":"Qin","year":"2023","journal-title":"Lancet"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2021.11.030","article-title":"Updated efficacy and safety data from imbrave150: atezolizumab plus bevacizumab vs. Sorafenib for unresectable hepatocellular carcinoma","volume":"76","author":"Cheng","year":"2022","journal-title":"J Hepatol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(21)00252-7","article-title":"Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): A randomised, open-label, phase 2\u20133 study","volume":"22","author":"Ren","year":"2021","journal-title":"Lancet Oncol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhepr.2021.100347","article-title":"ALBI grade: evidence for an improved model for liver functional estimation in patients with hepatocellular carcinoma","volume":"3","author":"Demirtas","year":"2021","journal-title":"JHEP Rep"},{"key":"B16","doi-asserted-by":"publisher","first-page":"e7142","DOI":"10.1097\/md.0000000000007142","article-title":"Albumin-bilirubin (ALBI) score at admission predicts possible outcomes in patients with acute-on-chronic liver failure","volume":"96","author":"Chen","year":"2017","journal-title":"Med (Baltimore)"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.2147\/jhc.S462701","article-title":"ALBI grade enables risk stratification for bleeding events and refines prognostic prediction in advanced hcc following atezolizumab and bevacizumab","volume":"12","author":"Stefanini","year":"2025","journal-title":"J Hepatocell Carcinoma"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1097\/hep.0000000000001026","article-title":"Hepatic decompensation is the major driver of mortality in patients with HCC treated with atezolizumab plus bevacizumab: the impact of successful antiviral treatment","volume":"81","author":"Celsa","year":"2025","journal-title":"Hepatology"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1159\/000529996","article-title":"Albumin-bilirubin grade analyses of atezolizumab plus bevacizumab versus sorafenib in patients with unresectable hepatocellular carcinoma: A post hoc analysis of the phase iii imbrave150 study","volume":"12","author":"Kudo","year":"2023","journal-title":"Liver Cancer"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1007\/s00432-023-04775-2","article-title":"A real-world analysis of survival and cost-effectiveness of sintilimab plus bevacizumab biosimilar regimen in patients with advanced hepatocellular carcinoma","volume":"149","author":"Zeng","year":"2023","journal-title":"J Cancer Res Clin Oncol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-001033","article-title":"Post-registration experience of nivolumab in advanced hepatocellular carcinoma: an international study","volume":"8","author":"Fessas","year":"2020","journal-title":"J Immunother Cancer"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1159\/000533991","article-title":"Safety and efficacy of atezolizumab\/bevacizumab in patients with hepatocellular carcinoma and impaired liver function: A systematic review and meta-analysis","volume":"13","author":"Pasta","year":"2024","journal-title":"Liver Cancer"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1111\/j.1478-3231.2008.01957.x","article-title":"Prognostic indicators in hepatocellular carcinoma: A systematic review of 72 studies","volume":"29","author":"Tandon","year":"2009","journal-title":"Liver Int"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1002\/hep.27443","article-title":"Prognosis of untreated hepatocellular carcinoma","volume":"61","author":"Giannini","year":"2015","journal-title":"Hepatology"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1111\/liv.15464","article-title":"Treatment patterns for hepatocellular carcinoma in patients with child-pugh class B and their impact on survival: A Korean nationwide registry study","volume":"42","author":"Jeon","year":"2022","journal-title":"Liver Int"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2021.04.047","article-title":"Checkmate 040 cohort 5: A phase I\/II study of nivolumab in patients with advanced hepatocellular carcinoma and child-pugh B cirrhosis","volume":"75","author":"Kudo","year":"2021","journal-title":"J Hepatol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2016.07.020","article-title":"Observational registry of sorafenib use in clinical practice across child-pugh subgroups: the gideon study","volume":"65","author":"Marrero","year":"2016","journal-title":"J Hepatol"},{"key":"B28","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ejca.2018.09.031","article-title":"Sorafenib as first-line therapy in patients with advanced child-pugh B hepatocellular carcinoma-a meta-analysis","volume":"105","author":"McNamara","year":"2018","journal-title":"Eur J Cancer"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1177\/17588359221116608","article-title":"Lenvatinib in patients with\u00a0unresectable hepatocellular carcinoma who progressed to child-pugh B liver function","volume":"14","author":"Huynh","year":"2022","journal-title":"Ther Adv Med Oncol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1002\/hep.32468","article-title":"Preliminary evidence of safety and tolerability of atezolizumab plus bevacizumab in patients with hepatocellular carcinoma and child-pugh a and B cirrhosis: A real-world study","volume":"76","author":"D'Alessio","year":"2022","journal-title":"Hepatology"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1177\/17588359221148541","article-title":"Atezolizumab plus bevacizumab in patients with child-pugh B advanced hepatocellular carcinoma","volume":"15","author":"Cheon","year":"2023","journal-title":"Ther Adv Med Oncol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1093\/oncolo\/oyae142","article-title":"Atezolizumab plus bevacizumab as first-line systemic therapy for hepatocellular carcinoma: A multi-institutional cohort study","volume":"29","author":"Storandt","year":"2024","journal-title":"Oncologist"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2024.08.028","article-title":"Easl clinical practice guidelines on the management of hepatocellular carcinoma","volume":"82","year":"2025","journal-title":"J Hepatol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2006.11.015","article-title":"Bevacizumab: an angiogenesis inhibitor for the treatment of solid Malignancies","volume":"28","author":"Shih","year":"2006","journal-title":"Clin Ther"},{"key":"B35","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.critrevonc.2019.05.016","article-title":"Management of targeted therapies in cancer patients with chronic kidney disease, or on haemodialysis: an associazione italiana di oncologia medica (Aiom)\/societa' Italiana di nefrologia (Sin) multidisciplinary consensus position paper","volume":"140","author":"Silvestris","year":"2019","journal-title":"Crit Rev Oncol Hematol"},{"key":"B36","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/s40364-022-00363-7","article-title":"Sintilimab for the treatment of non-small cell lung cancer","volume":"10","author":"Zhang","year":"2022","journal-title":"biomark Res"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1007\/s12072-024-10732-z","article-title":"Apasl clinical practice guidelines on systemic therapy for hepatocellular carcinoma-2024","volume":"18","author":"Lau","year":"2024","journal-title":"Hepatol Int"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0073492","article-title":"Bevacizumab attenuates hepatic fibrosis in rats by inhibiting activation of hepatic stellate cells","volume":"8","author":"Huang","year":"2013","journal-title":"PloS One"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2007-0174","article-title":"Early antiangiogenic activity of bevacizumab evaluated by computed tomography perfusion scan in patients with advanced hepatocellular carcinoma","volume":"13","author":"Zhu","year":"2008","journal-title":"Oncologist"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1080\/19420862.2019.1654303","article-title":"Durable blockade of pd-1 signaling links preclinical efficacy of sintilimab to its clinical benefit","volume":"11","author":"Wang","year":"2019","journal-title":"MAbs"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2018.29","article-title":"Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges","volume":"15","author":"Fukumura","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2024.102622","article-title":"Immune checkpoint inhibitors and anti-vascular endothelial growth factor antibody\/tyrosine kinase inhibitors with or without transarterial chemoembolization as first-line treatment for advanced hepatocellular carcinoma (Chance2201): A target trial emulation study","volume":"72","author":"Jin","year":"2024","journal-title":"EClinicalMedicine"},{"key":"B43","doi-asserted-by":"publisher","first-page":"S26","DOI":"10.1002\/jcph.990","article-title":"Clinical pharmacology considerations for the development of immune checkpoint inhibitors","author":"Sheng","year":"2017","journal-title":"J Clin Pharmacol"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1053\/jhep.2002.32089","article-title":"Prognostic prediction and treatment strategy in hepatocellular carcinoma","volume":"35","author":"Bruix","year":"2002","journal-title":"Hepatology"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1681663\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T05:21:53Z","timestamp":1762320113000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1681663\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,5]]},"references-count":44,"alternative-id":["10.3389\/fonc.2025.1681663"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2025.1681663","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,5]]},"article-number":"1681663"}}